HF Advisory Group LLC Acquires 146,444 Shares of IQVIA Holdings Inc. $IQV

HF Advisory Group LLC lifted its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 1,791.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 154,618 shares of the medical research company’s stock after purchasing an additional 146,444 shares during the period. IQVIA accounts for about 1.3% of HF Advisory Group LLC’s portfolio, making the stock its 11th biggest position. HF Advisory Group LLC’s holdings in IQVIA were worth $34,852,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the business. Boston Partners acquired a new stake in shares of IQVIA during the 3rd quarter worth approximately $676,698,000. AQR Capital Management LLC increased its stake in IQVIA by 130.2% in the second quarter. AQR Capital Management LLC now owns 1,555,298 shares of the medical research company’s stock valued at $245,099,000 after purchasing an additional 879,701 shares in the last quarter. Qube Research & Technologies Ltd boosted its position in shares of IQVIA by 86.0% during the 2nd quarter. Qube Research & Technologies Ltd now owns 1,250,174 shares of the medical research company’s stock worth $197,015,000 after purchasing an additional 578,035 shares in the last quarter. Arrowstreet Capital Limited Partnership grew its stake in shares of IQVIA by 193.1% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 848,771 shares of the medical research company’s stock valued at $133,758,000 after buying an additional 559,190 shares during the period. Finally, Vontobel Holding Ltd. increased its position in IQVIA by 909.1% in the 3rd quarter. Vontobel Holding Ltd. now owns 550,430 shares of the medical research company’s stock valued at $104,549,000 after buying an additional 495,884 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors.

IQVIA Trading Up 1.2%

Shares of IQVIA stock opened at $172.66 on Thursday. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.09. The stock has a fifty day simple moving average of $182.63 and a 200 day simple moving average of $204.96. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $247.04. The company has a market capitalization of $29.30 billion, a P/E ratio of 21.97, a price-to-earnings-growth ratio of 1.65 and a beta of 1.39.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Thursday, February 5th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.40 by $0.02. The firm had revenue of $4.36 billion for the quarter, compared to the consensus estimate of $4.24 billion. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.12 EPS. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. On average, sell-side analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on IQV shares. Citigroup cut their price target on IQVIA from $230.00 to $200.00 and set a “neutral” rating on the stock in a report on Friday, February 6th. TD Cowen raised IQVIA from a “hold” rating to a “buy” rating and upped their target price for the stock from $174.00 to $213.00 in a research report on Monday, March 9th. Barclays upgraded IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 target price on the stock in a report on Friday, March 6th. BMO Capital Markets set a $250.00 price target on shares of IQVIA in a research note on Friday, February 6th. Finally, Mizuho set a $215.00 price objective on shares of IQVIA in a research note on Monday, February 23rd. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, IQVIA currently has an average rating of “Buy” and an average target price of $229.13.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.